Safety and efficacy of brentuximab vedotin as a treatment for lymphoproliferative disorders in primary immunodeficiencies

Thomas Pincez; Julie Bruneau; Laureline Berteloot; Eve Piekarski; Caroline Thomas; Ambroise Marçais; Amélie Trinquand; Martin Castelle; Nicolas Garcelon; Dominique Plantaz; Morgane Cheminant; Despina Moshous; Thierry Jo Molina; Olivier Hermine; Elizabeth Macintyre; Alain Fischer; Stéphane Blanche; Felipe Suarez; Bénédicte Neven

doi:10.3324/haematol.2019.230276

Safety and efficacy of brentuximab vedotin as a treatment for lymphoproliferative disorders in primary immunodeficiencies

Haematologica. 2020 Sep 1;105(9):e461-464. doi: 10.3324/haematol.2019.230276.

Authors

Thomas Pincez¹, Julie Bruneau², Laureline Berteloot³, Eve Piekarski⁴, Caroline Thomas⁵, Ambroise Marçais⁶, Amélie Trinquand⁷, Martin Castelle¹, Nicolas Garcelon⁸, Dominique Plantaz⁹, Morgane Cheminant⁶, Despina Moshous¹⁰, Thierry Jo Molina¹¹, Olivier Hermine⁶, Elizabeth Macintyre¹², Alain Fischer¹³, Stéphane Blanche¹⁰, Felipe Suarez⁶, Bénédicte Neven¹⁴

Affiliations

¹ Pediatric Hematology-Immunology and Rheumatology Department, Hôpital Necker-Enfants Malades, AP-HP, Paris.
² Pathology Department, Hôpital Necker-Enfants Malades, AP-HP, Paris; Paris University, Paris; INSERM UMR 1163, Institut Imagine, Paris.
³ Medical Imaging Department, Hôpital Necker-Enfants Malades, APHP, Paris.
⁴ Nuclear Medicine Department, Hôpital Bichat-Claude Bernard, AP-HP, Paris.
⁵ Pediatric Oncology-Hematology Department, Hôpital Enfant-Adolescent, CHU Nantes, Nantes.
⁶ Paris University, Paris; INSERM UMR 1163, Institut Imagine, Paris; Department of Hematology, Hôpital Necker-Enfants Malades, AP-HP, Paris.
⁷ Laboratory of Onco-Hematology, Hôpital Necker-Enfants Malades, AP-HP, Paris.
⁸ Paris University, Paris; INSERM UMR 1163, Institut Imagine, Paris.
⁹ Pediatric Hematology-Oncology Department, Grenoble University Hospital, Grenoble.
¹⁰ Pediatric Hematology-Immunology and Rheumatology Department, Hôpital Necker-Enfants Malades, AP-HP, Paris; Paris University, Paris; INSERM UMR 1163, Institut Imagine, Paris.
¹¹ Pathology Department, Hôpital Necker-Enfants Malades, AP-HP, Paris; Paris University, Paris.
¹² Paris University, Paris; Laboratory of Onco-Hematology, Hôpital Necker-Enfants Malades, AP-HP, Paris; INSERM UMR 1151, Institut Necker-Enfants Malades, Paris.
¹³ Pediatric Hematology-Immunology and Rheumatology Department, Hôpital Necker-Enfants Malades, AP-HP, Paris; Paris University, Paris; INSERM UMR 1163, Institut Imagine, Paris; Collège de France, Paris, France.
¹⁴ Pediatric Hematology-Immunology and Rheumatology Department, Hôpital Necker-Enfants Malades, AP-HP, Paris; Paris University, Paris; INSERM UMR 1163, Institut Imagine, Paris. benedicte.neven@aphp.fr.

No abstract available

Publication types

Letter

MeSH terms

Brentuximab Vedotin
Humans
Immunoconjugates* / adverse effects
Ki-1 Antigen
Lymphoproliferative Disorders* / drug therapy
Treatment Outcome

Substances

Immunoconjugates
Ki-1 Antigen
Brentuximab Vedotin

Grants and funding

Funding: this research did not receive any specific funding from agencies or organizations in the public, commercial, or not-for-profit sectors.